Welcome to our dedicated page for Oppenheimer Hld news (Ticker: OPY), a resource for investors and traders seeking the latest updates and insights on Oppenheimer Hld stock.
Oppenheimer Holdings Inc. (NYSE: OPY) is a middle market investment bank and full service broker-dealer active in the investment banking and securities industry. Through its subsidiaries, including Oppenheimer & Co. Inc., the firm reports news on retail securities brokerage, institutional sales and trading, investment banking, equity and fixed income research, market-making, trust services, and investment advisory and asset management services.
The OPY news flow frequently includes quarterly earnings releases detailing segment results for Wealth Management and Capital Markets, trends in assets under management, and commentary from management on market conditions. Investors can follow updates on advisory and underwriting activity, equities and fixed income trading volumes, and changes in revenue components such as commissions, advisory fees, and bank deposit sweep income.
Company announcements also highlight capital actions and corporate events, such as the declaration of quarterly and special cash dividends on Class A non-voting and Class B voting common stock, as reported in press releases and related Form 8-K filings. In addition, Oppenheimer regularly reports on senior hires and team expansions across its platform, including appointments in Healthcare Equity Capital Markets, biotech research, public finance investment banking, cash equity sales and trading, and regional wealth management leadership.
Other OPY news items describe the evolution of the firm’s Custody and Prime Services (CAPS) platform and the expansion of its global credit and high yield and distressed businesses in the U.S., Europe, and Asia. For readers tracking OPY, this news page offers a centralized view of earnings updates, strategic hires, platform developments, and capital-related announcements drawn from company press releases and disclosures.
Oppenheimer Holdings has announced a new share repurchase program, allowing the purchase of up to 543,000 shares of its Class A non-voting common stock, about 5% of the total outstanding shares. This program adds to the previous authorization of 144,034 shares, totaling 687,034 shares available for repurchase. The repurchases will be executed in the open market using available cash, aligning with regulatory requirements. Oppenheimer emphasizes that the timing and volume of repurchases will depend on market conditions and does not obligate the company to buy a specific number of shares.
Oppenheimer & Co. has appointed Kevin Monaco as Managing Director and Regional Director for its Private Client Division in Southern California. Based in the Los Angeles office, Monaco brings significant experience, having previously served roles at D.A. Davidson, Wells Fargo, and Morgan Stanley. His expertise in recruiting advisory talent and understanding market dynamics positions him to enhance Oppenheimer's services for wealth management. This strategic hire aims to further establish Oppenheimer's presence in a competitive market.
Oppenheimer has appointed Rabi Karki as Head of Asset Management & Wealth Management for EMEA. Based in London, Karki brings over 20 years of experience, including roles at Barclays and J.P. Morgan. He will collaborate with U.S. counterparts to enhance Oppenheimer's financial advisory services. CEO Max Lami highlighted Karki's industry insights and potential to provide value to clients. This appointment is expected to strengthen Oppenheimer's presence in the asset management sector across Europe and beyond.
Oppenheimer & Co. Inc. will host its fifth annual Blockchain and Digital Assets Summit on November 17, 2022, a virtual event showcasing key participants in the blockchain sector. Notable companies attending include Blockchain.com, Coinbase, and Fidelity Digital Assets. Analysts Timothy Horan and Owen Lau emphasize the transformative potential of blockchain in creating new internet access and decentralized finance opportunities. The Summit will feature discussions on trends in DeFi, NFTs, payments, capital markets, and regulatory aspects, aimed at facilitating industry dialogue.
Oppenheimer & Co. Inc. announced the successful recruitment of the Meridian Wealth Group, expanding its Nashville office, which opened in March 2022. Led by industry veteran John Wade, the addition aims to enhance services for high-net-worth clients in a rapidly growing market. The Meridian team emphasizes customized solutions and client-focused service. Oppenheimer is committed to providing these new partners with tools and resources for long-term growth, reflecting its dedication to expanding its footprint in economically vibrant areas.
Oppenheimer Holdings reported third-quarter 2022 net income of $4.5 million ($0.40 per share), a significant decline from $26.3 million ($2.07 per share) in Q3 2021. Revenue fell by 6.7% to $294.1 million, driven by challenging market conditions and an adverse arbitration decision. Key earnings segments showed mixed results: Private Client revenue increased 11% to $178.6 million, while Capital Markets dropped 29.3% to $90.9 million. Despite these challenges, the firm maintained a robust balance sheet, with strong regulatory capital and increased book value per share to $70.23.
Oppenheimer & Co. Inc. has expanded its Global Fund Placement and Advisory Group with the addition of Charles Buisseret as Managing Director and Makayla Stephens as Director. Both will work in the U.S. alongside a cohesive team previously united at another firm. This strategic move aims to enhance services for alternative investment firms, particularly in primary funds and GP stakes. With this expansion, Oppenheimer continues to strengthen its private markets capabilities, crucial for its core sectors like Technology and Healthcare.
Summary not available.
Oppenheimer & Co. Inc. has appointed Joel Sendek as Managing Director and Head of Healthcare Life Sciences Equity Research, bolstering its research team amid evolving industry opportunities. Sendek, with extensive experience as a biotech analyst and CFO at several companies, joins to provide enhanced insights for investors in biotechnology and pharmaceuticals. His leadership aims to meet growing investor demand for informed analysis in this critical sector, as emphasized by executives John Parks and Michael Margolis during the announcement.
Oppenheimer & Co. Inc. has appointed Brad Watkins as Chief Financial Officer, effective August 1, 2022. With extensive experience in the financial services sector, notably at KPMG, Watkins will oversee Oppenheimer's financial operations and long-term budget planning. He joins at a pivotal time for the firm, which aims to enhance its operating model and drive growth. Chairman and CEO Albert G. Lowenthal emphasizes Watkins' expertise will be crucial as the company navigates an evolving market landscape.